Related Experiment Video
Updated: Aug 27, 2025
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Effects of scoparone on non-alcoholic fatty liver disease revealed by RNA sequencing
Xiaoyan Huang1,2, Ya Gao1,2, Houkang Cao1
1Pharmacology Laboratory of Prevention and Treatment of High Incidence of Disease, Guilin Medical University, Guilin, China.
Abstract:
Scoparone (SCO) is known to have curative effect of alleviating liver injury. The purpose of this study was to observe the therapeutic effect and possible mechanism of SCO against high-fat diet (HFD) induced non-alcoholic liver disease (NAFLD) through in vivo experiments and RNA sequencing. Male Kunming mice were fed with HFD for 8 weeks to establish a mouse model of NAFLD, and SCO was used to treat NAFLD. Histopathology and biochemical indicators were used to evaluate the liver injury and the efficacy of SCO. RNA sequencing analysis was performed to elucidate the hepatoprotective mechanism of SCO. Finally, the differentially expressed genes of cholesterol synthesis and fatty acid (triglyceride) synthesis pathways were verified by quantitative real-time polymerase chain reaction (qRT-PCR) and western blot. The histopathological results showed that HFD could lead to significant steatosis in mice, while SCO could alleviate liver steatosis remarkably in NAFLD mice. The determination of biochemical indicators showed that SCO could inhibit the increased serum transaminase activity and liver lipid level induced by HFD. RNA sequencing analysis of liver tissues found that 2742 and 3663 genes were significantly changed by HFD and SCO, respectively. SCO reversed the most of genes involved in cholesterol synthesis and fatty acid (triglyceride) metabolism induced by HFD. the results of the validation experiment were mostly consistent with the RNA sequencing. SCO alleviated liver injury and steatosis in NAFLD mice, which may be closely related to the regulation of cholesterol and fatty acid (triglyceride) metabolism.
Insights
Scoparone (SCO) effectively alleviates high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) in mice. It works by regulating cholesterol and fatty acid metabolism, reducing liver steatosis and injury.
Area of Science:
- Hepatology
- Biochemistry
- Molecular Biology
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a growing health concern.
- High-fat diets (HFD) are a primary driver of NAFLD.
- Scoparone (SCO) is recognized for its potential liver-protective properties.
Purpose of the Study:
- To investigate the therapeutic effects of SCO on HFD-induced NAFLD in a mouse model.
- To elucidate the underlying molecular mechanisms of SCO's hepatoprotective action using RNA sequencing.
Main Methods:
- Establishment of a NAFLD mouse model using HFD for 8 weeks.
- Treatment of NAFLD mice with SCO.
- Histopathological examination and biochemical analysis of liver injury.
- RNA sequencing to analyze gene expression changes.
- Validation of key gene targets using qRT-PCR and Western blot.
Main Results:
- HFD induced significant liver steatosis and elevated serum transaminase levels.
- SCO treatment markedly reduced liver steatosis and normalized biochemical indicators.
- RNA sequencing revealed SCO reversed HFD-induced alterations in cholesterol and fatty acid metabolism genes.
- Validation experiments confirmed RNA sequencing findings.
Conclusions:
- SCO demonstrates significant therapeutic efficacy against HFD-induced NAFLD.
- SCO's mechanism involves the regulation of cholesterol and fatty acid (triglyceride) metabolism.
- SCO holds promise as a potential treatment for NAFLD.
